Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Almirall, headquartered in Barcelona, Spain, announced it is buying five dermatology products from Allergan. Those include Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), Cordran Tape (fludroxycortide) and Seysara (sarecycline).
BeiGene, a biotech company based in Beijing, China and Cambridge, Massachusetts, announced it priced its initial public offering (IPO) on the Hong Kong stock exchange.
Chinese biotech company Ascletis Pharma debuted on the Hong Kong stock exchange, rising as much as 6.4 percent, but ending the day where it started.
The Cancer Prevention Institute of California (CPIC), located in Fremont, California, announced it was disbanding after 44 years. The reason for the closing, it indicates, is lack of federal funding.
Only a matter of days after Roche filed its second-quarter financial report, it’s had plenty of news to report.
In March, San Diego-based Orexigen Therapeutics filed for bankruptcy. Back in April, Orexigen entered into an asset purchase deal with Nalpropion Pharmaceuticals to sell most of its assets, subject to court approval.
Liquidia Technologiesnlaunched a successful initial public offering on July 25, raising $50 million. Neal Fowler, the company’s chief executive officer, and Kevin Gordon, Liquidia’s president and chief financial officer, took time out to talk with BioSpace about the company and where it’s headed.
Many analysts and investors were holding their breaths, waiting to see what Biogen would say at yesterday’s second-quarter financial report. The financials weren’t the focus, however, but what the Cambridge, Massachusetts biotech had to say about its pipeline, especially for Alzheimer’s disease, was.
Shares of Nabriva Therapeutics are rising this morning after the company announced it acquired privately-held Zavante Therapeutics.
Biogen reported strong sales for the second quarter, with total revenues of $3.4 billion, up 9 percent compared to the same period in 2017.